Although androgen excess is considered detrimental to women's health and fertility, global and ovarian granulosa cell-specific androgen-receptor (AR) knockout mouse models have been used to show that androgen actions through ARs are actually necessary for normal ovarian function and female fertility. Here we describe two AR-mediated pathways in granulosa cells that regulate ovarian follicular development and therefore female fertility. First, we show that androgens attenuate follicular atresia through nuclear and extranuclear signaling pathways by enhancing expression of the microRNA (miR) miR-125b, which in turn suppresses proapoptotic protein expression. Second, we demonstrate that, independent of transcription, androgens enhance follicle-stimulating hormone (FSH) receptor expression, which then augments FSHmediated follicle growth and development. Interestingly, we find that the scaffold molecule paxillin regulates both processes, making it a critical regulator of AR actions in the ovary. Finally, we report that low doses of exogenous androgens enhance gonadotropin-induced ovulation in mice, further demonstrating the critical role that androgens play in follicular development and fertility. These data may explain reported positive effects of androgens on ovulation rates in women with diminished ovarian reserve. Furthermore, this study demonstrates mechanisms that might contribute to the unregulated follicle growth seen in diseases of excess androgens such as polycystic ovary syndrome. O ther than the obligatory role of androgens as estrogen precursors in steroidogenesis (1), little is known about the direct involvement of androgens in the female ovary. For many decades, excess androgens in women have been considered detrimental to women's health, as diseases such as polycystic ovary syndrome (PCOS) are associated with reduced fertility. In the past, these negative effects of androgens on female fertility were thought to occur primarily at the level of the hypothalamus and pituitary (2, 3), although important data across different species (4-7) suggested that androgens could also directly promote follicle growth (8, 9). Attitudes about androgen actions in female fertility changed with the development of global androgenreceptor knockout (ARKO) mice (10-12). The female ARKO mice had considerable reproductive defects, with decreased fertility, defective follicular development, reduced ovulation, and premature ovarian failure. In other words, the phenotype of these ARKO mice suggested that androgen signaling might actually be important for normal female reproductive health. Intriguingly, through the generation of granulosa cell (GC)-specific ARKO mice, we (13) and then others (14) demonstrated that essentially all the observed reproductive phenotypes in the complete AR-null mice are caused by androgen actions in GCs. These results highlighted that, with regard to fertility, androgen signaling in the ovary is at least as important as androgen signaling in the pituitary or hypothalamus. By using this GC-specific ARK...
The physiological significance of androgens in female reproduction was unclear until female mice with global knockout of androgen receptor (AR) expression were found to have reduced fertility with abnormal ovarian function. However, because ARs are expressed in a myriad of reproductive tissues, including the hypothalamus, pituitary, and various ovarian cells, the role of tissue-specific ARs in regulating female fertility remained unknown. To examine the importance of ovarian ARs in female reproduction, we generated granulosa cell (GC)- and oocyte-specific AR-knockout (ARKO) mice by crossing AR-flox mice with MisRIIcre (GC-specific) or growth differentiation factor growth differentiation factor-9cre (oocyte-specific) mice. Relative to heterozygous and wild-type mice, GC-specific ARKO mice had premature ovarian failure and were subfertile, with longer estrous cycles and fewer ovulated oocytes. In addition, ovaries from GC-specific knockout mice contained more preantral and atretic follicles, with fewer antral follicles and corpus lutea. Finally, in vitro growth of follicles from GC-specific AR-null mice was slower than follicles from wild-type animals. In contrast to GC-specific AR-null mice, fertility, estrous cycles, and ovarian morphology of oocyte-specific ARKO mice were normal, although androgens no longer promoted oocyte maturation in these animals. Together, our data indicate that nearly all reproductive phenotypes observed in global ARKO mice can be explained by the lack of AR expression in GCs. These GC-specific ARs appear to promote preantral follicle growth and prevent follicular atresia; thus they are essential for normal follicular development and fertility.
2 Genomic actions involve binding of androgens to ARs, which then translocate to the nucleus, bind to androgen-response elements, and alter gene expression. In contrast, ARs also induce rapid nongenomic signals that are generally mediated by cross-talk between the AR and either G-proteins or growth factor receptors (1-4). Although transcriptional effects of androgens have been extensively studied, mechanisms regulating nongenomic actions of androgens are poorly understood.One potential regulator of nongenomic androgen actions is paxillin. Paxillin is a multidomain adaptor protein that integrates many signals from integrins, cell surface receptors, and growth factors (10, 11). Through these interactions, paxillin regulates a variety of physiological functions, including matrix organization, cell motility, tissue remodeling, metastasis, gene expression, cell survival, and proliferation (10, 11). Paxillin is comprised of multiple structural domains that modulate protein-protein interactions (10) and numerous serine/threonine and tyrosine phosphorylation targets that act as docking sites for various signaling proteins. Phosphorylation of these sites by growth factor receptor-tyrosine kinases, Src kinases, and serine/threonine kinases regulate adaptor molecule binding that ultimately coordinates complex cell signaling pathways (10). The importance of paxillin in normal physiological functions is further evident from global paxillin knock-out studies, demonstrating that ablation of paxillin in mice is embryonic lethal (12,13).We previously demonstrated that in Xenopus oocytes, paxillin is essential for non-genomic androgen-induced Erk signaling and subsequent Erk-mediated oocyte maturation (5). Specifically, paxillin is required for synthesis and activation of MOS (the germ cell Raf homolog), which then promotes MEK and subsequently Erk signaling (5). Interestingly, Erk-mediated phosphorylation of paxillin is also required for androgen-induced oocyte maturation. Thus, in oocytes, paxillin is both an affector and effector of Erk signaling.Here we significantly extend our findings in Xenopus oocytes to a mammalian somatic system. Given the well defined function of androgens and Erk signaling (3, 6 -8) in prostate cancer
In prostate cancer, the signals that drive cell proliferation change as tumors progress from castration-sensitive (androgen-dominant) to castration-resistant states. While the mechanisms underlying this change remain uncertain, characterization of common signaling components that regulate both stages of prostate cancer proliferation is important for developing effective treatment strategies. Here, we demonstrate that paxillin, a known cytoplasmic adaptor protein, regulates both androgen-and EGF-induced nuclear signaling. We show that androgen and EGF promoted MAPK-dependent phosphorylation of paxillin, resulting in nuclear translocation of paxillin. We found nuclear paxillin could then associate with androgen-stimulated androgen receptor (AR). This complex bound AR-sensitive promoters, retaining AR within the nucleus and regulating ARmediated transcription. Nuclear paxillin also complexed with ERK and ELK1, mediating c-FOS and cyclin D1 expression; this was followed by proliferation. Thus, paxillin is a liaison between extranuclear MAPK signaling and nuclear transcription in response to androgens and growth factors, making it a potential regulator of both castration-sensitive and castration-resistant prostate cancer. Accordingly, paxillin was required for normal growth of human prostate cancer cell xenografts, and its expression was elevated in human prostate cancer tissue microarrays. Paxillin is therefore a potential biomarker for prostate cancer proliferation and a possible therapeutic target for prostate cancer treatment. IntroductionProstate cancer is associated with significant morbidity and mortality and is the second most common cancer among men worldwide. One feature of prostate cancer progression is its apparent change in androgen responsiveness over time. At diagnosis, locally advanced prostate cancers are treated successfully by prostatectomy, irradiation, and/or anti-androgen therapy, suggesting that tumor cells are dependent on androgens for continued growth and survival. In contrast, despite treatment, many advanced tumors enter a more aggressive castration-resistant state after 18-24 months. This observation suggests fundamental changes in the extracellular triggers and intracellular signaling pathways that regulate proliferation and cell migration (1-3) in aggressive tumors. The reasons for this dramatic transformation in phenotype are not well understood. However, several likely interconnected mechanisms of castration resistance have been proposed. For example, alterations in intraprostatic androgen production or metabolism ("intracrine" androgen production) in castration-resistant prostate cancer (4, 5) could lead to elevated local androgen concentrations in the setting of low serum androgen levels. Alternatively, the abundance or activity of androgen receptors (ARs) and their various transcriptional coregulators might be modified in castration-resistant prostate cancer cells so that they respond to lower concentrations of androgen or other steroids (6). Finally, prostate cancer cells might ad...
For many decades, elevated androgens in women have been associated with poor reproductive health. However, recent studies have shown that androgens play a crucial role in women's fertility. The following review provides an overall perspective about how androgens and androgen receptor-mediated actions regulate normal follicular development, as well as discuss emerging concepts, latest perceptions, and controversies regarding androgen actions and signaling in the ovary.
An increasing body of evidence suggests that immune-mediated processes affect female reproductive success at multiple levels. Crosstalk between endocrine and immune systems regulates a large number of biological processes that affect target tissues, and this crosstalk involves gene expression, cytokine and/or lymphokine release and hormone action. In addition, endocrine-immune interactions have a major role in the implantation process of the fetal (paternally derived) semi-allograft, which requires a reprogramming process of the maternal immune system from rejection to temporary tolerance for the length of gestation. Usually, the female immune system is supportive of all of these processes and, therefore, facilitates reproductive success. Abnormalities of the female immune system, including autoimmunity, potentially interfere at multiple levels. The relevance of the immune system to female infertility is increasingly recognized by investigators, but clinically is often not adequately considered and is, therefore, underestimated. This Review summarizes the effect of individual autoimmune endocrine diseases on female fertility, and points towards selected developments expected in the near future.
Tissue infiltration and elevated peripheral circulation of granulocytic myeloid-derived cells is associated with poor outcomes in prostate cancer (PCa) and other malignancies. Although myeloid-derived cells have the ability to suppress T-cell function, little is known about the direct impact of these innate cells on prostate tumor growth. Here it is reported that granulocytic myeloid-derived suppressor cells (MDSCs) are the predominant tumor infiltrating cells in PCa xenografts established in athymic nude mice. MDSCs significantly increased in number in the peripheral circulation as a function of xenograft growth and were successfully depleted in vivo by Gr-1 antibody treatment. Importantly, MDSC depletion significantly decreased xenograft growth. We hypothesized that granulocytic MDSCs might exert their pro-tumorigenic actions in part through neutrophil elastase (ELA2/NE), a serine protease released upon granulocyte activation. Indeed, it was determined that NE is expressed by infiltrating immune cells and is enzymatically active in PCa xenografts and in prostate tumors of prostate-specific Pten-null mice. Importantly, treatment with sivelestat, a small-molecule inhibitor specific for NE, significantly decreased xenograft growth, recapitulating the phenotype of Gr-1 MDSC depletion. Mechanistically, NE activated mitogen-activated protein kinase (MAPK) signaling and induced MAPK-dependent transcription of the proliferative gene cFOS in PCa cells. Functionally, NE stimulated proliferation, migration, and invasion of PCa cells in vitro. Immunohistochemistry (IHC) on human PCa clinical biopsies revealed co-expression of NE and infiltrating CD33+ MDSCs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.